
Alternative Method developed by Accelera – Metodo alternativo sviluppato da Accelera
On September 21st were presented at the EU Commission Joint Research Center in Ispra the results of the method “Inhibition of thyroid hormones glucuronidation using liquid chromatography/mass spectrometry” developed by Accelera within the frame of the EU-NETVAL project, aimed at implementing new alternative (non-animal) methods to assess the potential disrupting effect of chemicals on the thyroid.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit 2023 in San Diego CA (Oct 16th-Oct 19th, 2023)
Nerviano Medical Sciences S.r.l., a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2023 summit that will be held in San Diego (CA) from October 16th to October 19th, 2023, with two poster presentations
(Click the title for the complete article)
Nerviano Medical Sciences Srl partecipa alla European Biotech Week 2023 / Nerviano Medical Sciences Srl participates in the European Biotech Week 2023
La EBW è una settimana di eventi e incontri in tutta Europa per raccontare le biotecnologie nei diversi settori di applicazione ad un pubblico vasto e diversificato, sottolineando il ruolo chiave che queste tecnologie hanno nel migliorare la qualità della vita di tutti noi.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. announces preclinical data on NMS-P945, its novel proprietary payload-linker for ADC generation, published in Molecular Cancer Therapeutics
Nerviano, September 20, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A. and a clinical stage biotech, discovering and developing innovative therapies for the treatment of cancer, today announces the publication of preclinical data on NMS-P945 (link to article), its novel protease-cleavable thienoduocarmycin derivative payload-linker, with DNA damaging properties, in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
(Click the title for the complete article)
SIMIS Srl Announces Nomination of Laurent Contaut as the new CEO of SIMIS, a company part of NMS Group
SIMIS Srl (SIMIS), a NMS Group company, is pleased to announce the appointment of Laurent Contaut as the new Chief Executive Officer (CEO) of the organization, effective immediately. The appointment of Laurent comes at an exciting time for SIMIS, as the company continues to expand its services and drive innovation in the pharmaceutical and biotech industries.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. names Alberto Ocana, PhD, as Global Clinical Lead
NMS Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Alberto Ocana PhD, has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. In this pivotal role, Alberto will spearhead the company’s efforts to drive innovation, enhance patient outcomes, and strengthen our global partnerships.
(Click the title for the complete article)
NerPharMa Appoints Vittorio Montanaro as New Head of Quality to Strengthen Commitment to Excellence
NerPharMa Srl (part of NMS group), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Vittorio Montanaro as new Head of Quality, effective immediately. In this role, Vittorio will lead the Quality Assurance, Quality Control and Regulatory Affairs to ensure the highest standards of quality, safety and compliance across NerPharMa’s extensive range of services, offered through both Drug Substances and Drug Product divisions. Vittorio will cover also the role of Qualified Person.
(Click the title for the complete article)
Visit Accelera Team at the 57th Congress of the European Societies of Toxicology (EUROTOX 2023). Ljubljana, Slovenia, (September 10-13)
Visit Accelera Team at the 57th Congress of the European Societies of Toxicology (EUROTOX 2023). Ljubljana, Slovenia, (September 10-13)
(Click the title for the complete article)
Nerviano Medical Sciences Announces Enhanced US Executive Team: Terrence West, MBA, Expands Role as Chief Operating Officer
NERVIANO, IT and BOSTON, Mass., August 1, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US) in Boston. Terrence West, MBA, the company’s New Business, Virtual CEO has been appointed to the newly created position of Chief Operating Officer, effective immediately, to further drive the growth of NMS-US while continuing to oversee the strategic positioning of NMS-173, its IDH1/IDH2 Inhibitor Asset.
(Click the title for the complete article)
Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia
Nerviano 22 June 2023_Nerviano Medical Sciences Srl (NMS), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to announce the FDA Clearance of Investigational New Drug (IND) Application for NMS-03592088 (NMS-088), a novel, potent FLT3 inhibitor.
(Click the title for the complete article)
Our Archive





